Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.
Visani G, Ferrara F, Di Raimondo F, Loscocco F, Sparaventi G, Paolini S, Fuligni F, Gazzola A, Rossi M, Laginestra MA, Caraci MR, Riccardi C, Rocchi M, Visani A, Pileri SA, Piccaluga PP, Isidori A.
Visani G, et al. Among authors: visani a.
Leukemia. 2014 Apr;28(4):967-70. doi: 10.1038/leu.2014.31. Epub 2014 Jan 20.
Leukemia. 2014.
PMID: 24441289
Clinical Trial.
No abstract available.